CapsoVision (NASDAQ:CV) Rating Increased to Strong-Buy at Roth Capital

CapsoVision (NASDAQ:CV) was upgraded by stock analysts at Roth Capital to a “strong-buy” rating in a note issued to investors on Monday, Marketbeat.com reports. The brokerage currently has a $6.00 target price on the stock. Roth Capital’s target price indicates a potential upside of 53.45% from the stock’s previous close. Roth Capital also issued estimates for CapsoVision’s Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.35 EPS and FY2029 earnings at $0.58 EPS.

Several other brokerages also recently issued reports on CV. Benchmark started coverage on CapsoVision in a research report on Monday, July 28th. They issued a “speculative buy” rating and a $5.00 price objective for the company. Wall Street Zen raised CapsoVision to a “hold” rating in a report on Sunday, July 13th.

CapsoVision Stock Up 1.0%

Shares of NASDAQ CV opened at $3.91 on Monday. CapsoVision has a 52-week low of $3.49 and a 52-week high of $5.72.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.